Search

ATX-101

ATX-101 (medical), sodium deoxycholate for subcutaneous injection, is being evaluated as a treatment for the reduction of localized fat deposits. … ATX-101 demonstrates a relative selectivity for fat over other tissues.

TAK-754

Developed by Takeda, it is being investigated for the treatment of hemophilia A.[A259831]

Ligelizumab

Initial trials of ligelizumab suggest a greater efficacy over its predecessor for the treatment of CSU.[A242367] … [A242292] Ligelizumab is currently under investigation for the treatment of chronic spontaneous urticaria (CSU), an autoimmune-driven inflammatory condition.

Xamoterol

It modulates the sympathetic control of the heart but has no agonist action on β2-adrenoceptors.

Dilmapimod

Previous p38 MAP-kinase inhibitors have been hindered in development by liver toxicity. Methotrexate (common treatment for RA patients) also has potential liver toxicity.}

CXD101

CXD101 is under investigation in clinical trial NCT03873025 (A Study of CXD101 in Combination With Pembrolizumab for Relapsed or Refractory Diffuse Large B-cell Lymphoma).

Lanoteplase

Lomifylline

AVR118

of cancers); for its ability to stimulate the immune system to attack tumor cells (especially those cancer cells that have been damaged by chemotherapeutic agents) and for its ability to treat cachexia … AVR118 is being studied for the promise shown in its ability to mitigate the toxic side effects of other drugs (including those used to treat HIV infection and chemotherapeutic drugs employed in the treatment

Q-Derp1

Q-Derp1 is developed by Cytos Biotechnology as an immunodrug. It is an antigen for the prevention of various major chronic diseases. Derp1 is the dominant allergic protein found in dust mite feces.